Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Down Following Analyst Downgrade

Tandem Diabetes Care, Inc. (NASDAQ:TNDM)’s share price gapped down prior to trading on Friday after Wells Fargo & Company lowered their price target on the stock from $27.00 to $25.00. The stock had previously closed at $17.99, but opened at $15.83. Wells Fargo & Company currently has an overweight rating on the stock. Tandem Diabetes Care shares last traded at $16.5730, with a volume of 770,988 shares.

Several other equities analysts also recently commented on TNDM. Citigroup lowered their price objective on Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, September 30th. Royal Bank Of Canada reiterated an “outperform” rating and set a $26.00 target price (down from $30.00) on shares of Tandem Diabetes Care in a research report on Friday, August 7th. UBS Group started coverage on Tandem Diabetes Care in a research note on Tuesday, July 28th. They set a “neutral” rating and a $18.00 target price on the stock. Truist Financial lowered their price target on Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, September 24th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Tandem Diabetes Care in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Tandem Diabetes Care has an average rating of “Hold” and a consensus price target of $27.08.

Insider Transactions at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Christopher J. Twomey sold 1,700 shares of the company’s stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total transaction of $32,555.00. Following the sale, the director directly owned 24,434 shares in the company, valued at $467,911.10. This represents a 6.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is currently owned by company insiders.

Tandem Diabetes Care News Roundup

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Q3 revenue was $283.7 million, up 13.8% year over year and above analyst estimates of $265.9 million. The company’s loss of $0.10 per share was also narrower than expected. Tandem Q3 2026 financial results
• Positive Sentiment: Gross margin improved to 57%, up 2.7 percentage points from a year earlier. Tandem also reported about 33,000 pump shipments, supporting evidence of business growth. Tandem Q3 2026 financial results
• Positive Sentiment: Management forecast 2026 sales of $1.065 billion to $1.085 billion, giving investors a full-year revenue range to assess against the company’s growth trajectory. 2026 sales outlook and CEO transition
• Neutral Sentiment: Tandem named Jeannette Bankes as president and CEO as John Sheridan plans to retire at the end of 2026. Naming a successor provides advance notice, though investors may watch for details on strategic continuity during the transition. Tandem names Jeannette Bankes CEO

Institutional Trading of Tandem Diabetes Care

A number of institutional investors have recently bought and sold shares of the stock. First Light Asset Management LLC boosted its stake in Tandem Diabetes Care by 157.4% during the second quarter. First Light Asset Management LLC now owns 3,383,553 shares of the medical device company’s stock worth $51,058,000 after buying an additional 2,068,838 shares during the period. Defilade Capital Management L.P. bought a new position in Tandem Diabetes Care during the first quarter valued at $14,606,000. Quantinno Capital Management LP raised its stake in shares of Tandem Diabetes Care by 123.5% in the first quarter. Quantinno Capital Management LP now owns 653,870 shares of the medical device company’s stock valued at $12,535,000 after acquiring an additional 361,361 shares during the period. First Trust Advisors LP purchased a new stake in shares of Tandem Diabetes Care in the first quarter valued at $6,570,000. Finally, Principal Financial Group Inc. lifted its holdings in shares of Tandem Diabetes Care by 2.2% in the 1st quarter. Principal Financial Group Inc. now owns 331,541 shares of the medical device company’s stock worth $6,356,000 after acquiring an additional 7,279 shares during the last quarter.

Tandem Diabetes Care Stock Down 6.6%

The company’s fifty day moving average price is $17.74 and its 200-day moving average price is $18.90. The stock has a market cap of $1.17 billion, a P/E ratio of -18.18 and a beta of 1.59. The company has a debt-to-equity ratio of 4.62, a quick ratio of 2.65 and a current ratio of 3.18.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Thursday, November 5th. The medical device company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.15. The firm had revenue of $283.69 million during the quarter, compared to analysts’ expectations of $265.85 million. Tandem Diabetes Care had a negative net margin of 6.08% and a negative return on equity of 45.97%. The firm’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.31) EPS. Equities analysts forecast that Tandem Diabetes Care, Inc. will post -0.66 EPS for the current year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem’s product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.